BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 27144061)

  • 21. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next generation sequencing of acute myeloid leukemia: influencing prognosis.
    Ilyas AM; Ahmad S; Faheem M; Naseer MI; Kumosani TA; Al-Qahtani MH; Gari M; Ahmed F
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S5. PubMed ID: 25924101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular Genetic Testing for Acute Myeloid Leukemia].
    Janečková V; Semerád L; Ježíšková I; Dvořáková D; Čulen M; Šustková Z; Mayer J; Ráčil Z
    Klin Onkol; 2016; 29(6):411-418. PubMed ID: 27951719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
    Patel U; Luthra R; Medeiros LJ; Patel KP
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytogenetics in acute myeloid leukemia.
    Schoch C; Haferlach T
    Curr Oncol Rep; 2002 Sep; 4(5):390-7. PubMed ID: 12162912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia.
    Hasserjian RP
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101249. PubMed ID: 33762104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.
    Coles EC; Colita A; Momanu R; Berbec N; Ivanescu AM; Oprea M; Jardan D; Jardan C; Arghir A; Coriu D; Lupu AR
    J Med Life; 2012; 5(Spec Issue):36-43. PubMed ID: 31803284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in AML: prognostic and therapeutic implications.
    DiNardo CD; Cortes JE
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):348-355. PubMed ID: 27913501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
    Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Grönberg H
    Leukemia; 2017 Oct; 31(10):2029-2036. PubMed ID: 28167833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.
    Hussaini MO; Mirza AS; Komrokji R; Lancet J; Padron E; Song J
    Cancer Genomics Proteomics; 2018; 15(2):121-126. PubMed ID: 29496691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
    Leisch M; Jansko B; Zaborsky N; Greil R; Pleyer L
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30795628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
    Bullinger L; Döhner K; Döhner H
    J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia.
    King RL; Bagg A
    Methods Mol Biol; 2017; 1633():1-17. PubMed ID: 28735477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
    Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies.
    Morrissette JJ; Bagg A
    Clin Lab Med; 2011 Dec; 31(4):659-86, x. PubMed ID: 22118743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of recurrent gene mutations in acute myeloid leukemia.
    Yu J; Li Y; Zhang D; Wan D; Jiang Z
    Exp Hematol Oncol; 2020; 9():4. PubMed ID: 32231866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know.
    Arber DA
    Semin Hematol; 2019 Apr; 56(2):90-95. PubMed ID: 30926096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A three-gene expression-based risk score can refine the European LeukemiaNet AML classification.
    Wilop S; Chou WC; Jost E; Crysandt M; Panse J; Chuang MK; Brümmendorf TH; Wagner W; Tien HF; Kharabi Masouleh B
    J Hematol Oncol; 2016 Sep; 9(1):78. PubMed ID: 27585840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.